(Q37866288)

24 August 2017

1 reference

title

Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy (English)

1 reference

juvenile rheumatoid arthritis

24 August 2017

0 references

1 reference

Michael W Beresford

1

1 reference

24 August 2017

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

13

1 reference

24 August 2017

3

1 reference

24 August 2017

161-173

1 reference

https://scigraph.springernature.com/pub.10.2165/11588140-000000000-00000

24 August 2017

0 references

cites work

New advances in the management of juvenile idiopathic arthritis--1: non-biological therapy

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Juvenile idiopathic arthritis: classification, clinical presentation and current treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

A comprehensive review of the genetics of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Environmental factors and the geoepidemiology of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Possible environmental determinants of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

[Juvenile idiopathic arthritis--clinical subgroups and classification].

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Early diagnosis of temporomandibular joint involvement in juvenile idiopathic arthritis: a pilot study comparing clinical examination and ultrasound to magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

The detection of subclinical synovitis by ultrasound in oligoarticular juvenile idiopathic arthritis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Evidence-based outcomes of studies addressing diagnostic accuracy of MRI of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Developing outcome measures for paediatric rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Measuring clinical response and remission in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

International research networks in pediatric rheumatology: the PRINTO perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Patterns of clinical remission in select categories of juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

The PedsQL™* 4.0 as a Pediatric Population Health Measure: Feasibility, Reliability, and Validity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Improving the evidence base for treatment of juvenile idiopathic arthritis: the challenge and opportunity facing the MCRN/ARC Paediatric Rheumatology Clinical Studies Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Factors influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Medical treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Intra-articular corticosteroid injections in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Use of methotrexate in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Rational use of new and existing disease-modifying agents in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Recognition and management of macrophage activation syndrome in juvenile arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Biologic therapies in rheumatology: lessons learned, future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Update on biologics in juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Summary of worldwide pediatric malignancies reported after exposure to etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

At the horizon of innovative therapy in rheumatology: new biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

The German etanercept registry for treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588140-000000000-00000

When does a knee "need" a "joint" assessment?

21 January 2018

1 reference

12 December 2020

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

1 reference

12 December 2020

Juvenile idiopathic arthritis

1 reference

12 December 2020

Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease

1 reference

12 December 2020

Preliminary definition of improvement in juvenile arthritis

1 reference

12 December 2020

Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group

1 reference

12 December 2020

Autologous haematopoeitic stem cell rescue (AHSCR) for severe rheumatic disease in children: guidance for BSPAR members--executive summary

1 reference

12 December 2020

HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis.

1 reference

12 December 2020

Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis?

1 reference

12 December 2020

Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study

1 reference

12 December 2020

Growing pains: the ILAR classification of juvenile idiopathic arthritis

1 reference

12 December 2020

Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)

1 reference

12 December 2020

Biologic therapies in juvenile idiopathic arthritis: why and for whom?

1 reference

12 December 2020

Treatment of juvenile idiopathic arthritis with intra-articular triamcinolone hexacetonide: evaluation of clinical effectiveness correlated with circulating ANA and T gamma/delta + and B CD5+ lymphocyte populations of synovial fluid

1 reference

12 December 2020

BSPAR position statement on professionals working in paediatric rheumatology

1 reference

12 December 2020

The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials

1 reference

12 December 2020

Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis

1 reference

12 December 2020

Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.

1 reference

12 December 2020

Developing standards of care for patients with juvenile idiopathic arthritis

1 reference

12 December 2020

Focus on juvenile idiopathic arthritis according to the 2001 Edmonton revised classification from the International League of Associations for Rheumatology: an Italian experience.

1 reference

12 December 2020

Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria.

1 reference

12 December 2020

Treating children with arthritis: towards an evidence-based culture.

1 reference

12 December 2020

Juvenile idiopathic arthritis classification criteria: loopholes and diagnosis software.

1 reference

12 December 2020

Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis.

1 reference

12 December 2020

Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology.

1 reference

12 December 2020

The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ).

1 reference

12 December 2020

International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001

1 reference

12 December 2020

Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial

1 reference

12 December 2020

Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis.

1 reference

12 December 2020

Prospective evaluation of clinical and ultrasound findings in ankle disease in juvenile idiopathic arthritis: importance of ankle ultrasound

1 reference

12 December 2020

Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register.

1 reference

12 December 2020

Preliminary definition of disease flare in juvenile rheumatoid arthritis

1 reference

12 December 2020

Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration

1 reference

12 December 2020

BSPAR Standards of Care for children and young people with juvenile idiopathic arthritis

1 reference

12 December 2020

Classification of chronic arthritides of childhood (juvenile idiopathic arthritis): criticisms and suggestions to improve the efficacy of the Santiago-Durban criteria

1 reference

12 December 2020

Imaging juvenile idiopathic arthritis: assessing the modalities.

1 reference

12 December 2020

Evaluation of revised International League of Associations for Rheumatology classification criteria for juvenile idiopathic arthritis in Spanish children (Edmonton 2001)

1 reference

12 December 2020

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

1 reference

12 December 2020

10.2165/11588140-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

21500870

Dimensions Publication ID

24 August 2017

0 references

1 reference

PubMed ID

21500870